Search Results - "Masafumi Kurosumi"

Tissue distribution of aryl hydrocarbon receptor in the intestine: Implication of putative roles in tumor suppression by Ikuta, Togo, Kurosumi, Masafumi, Yatsuoka, Toshimasa, Nishimura, Yoji

“…Intestinal homeostasis is maintained by complex interactions between intestinal microorganisms and the gut immune system. Dysregulation of gut immunity may…”
Get full text

Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer by Kurozumi, Sasagu, Inoue, Kenichi, Matsumoto, Hiroshi, Fujii, Takaaki, Horiguchi, Jun, Oyama, Tetsunari, Kurosumi, Masafumi, Shirabe, Ken

“…Predictive utility of tumor-infiltrating lymphocytes (TILs) in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy (NAC) with concurrent…”
Get full text

Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer by Kurozumi, Sasagu, Kaira, Kyoichi, Matsumoto, Hiroshi, Kurosumi, Masafumi, Yokobori, Takehiko, Kanai, Yoshikatsu, Sekine, Chikako, Honda, Chikako, Katayama, Ayaka, Furuya, Mio, Shiino, Sho, Makiguchi, Takaya, Mongan, Nigel P., Rakha, Emad A., Oyama, Tetsunari, Fujii, Takaaki, Shirabe, Ken, Horiguchi, Jun

“…L-type amino acid transporter 1 (LAT1), also referred to as SLC7A5, is believed to regulate tumor metabolism and be associated with tumor proliferation. In…”
Get full text

Clinicopathological values of PD-L1 expression in HER2-positive breast cancer by Kurozumi, Sasagu, Inoue, Kenichi, Matsumoto, Hiroshi, Fujii, Takaaki, Horiguchi, Jun, Oyama, Tetsunari, Kurosumi, Masafumi, Shirabe, Ken

“…Several ongoing clinical trials are investigating the use of immuno-targeting therapy with programmed cell death protein-1 and programmed death-ligand 1…”
Get full text

Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study by Mikami, Yoshiki, Ueno, Takayuki, Yoshimura, Kenichi, Tsuda, Hitoshi, Kurosumi, Masafumi, Masuda, Shinobu, Horii, Rie, Toi, Masakazu, Sasano, Hironobu

“…The standardized assessment of Ki67 labeling index (LI) is of clinical importance to identify patients with primary breast cancer who could benefit from…”
Get full text

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index by Kurozumi, Sasagu, Matsumoto, Hiroshi, Hayashi, Yuji, Tozuka, Katsunori, Inoue, Kenichi, Horiguchi, Jun, Takeyoshi, Izumi, Oyama, Tetsunari, Kurosumi, Masafumi

“…The Ki67 labeling index (LI) is regarded as a significant prognostic marker in ER-positive/HER2-negative breast cancer patients. The expression of PgR has…”
Get full text

Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer by Kurozumi, Sasagu, Matsumoto, Hiroshi, Inoue, Kenichi, Tozuka, Katsunori, Hayashi, Yuji, Kurosumi, Masafumi, Oyama, Tetsunari, Fujii, Takaaki, Horiguchi, Jun, Kuwano, Hiroyuki

“…The preoperative endocrine prognostic index (PEPI) predicts survival after neoadjuvant endocrine therapy (NAE) using aromatase inhibitors (AIs) for women with…”
Get full text

Cryoablation as the primary treatment in a HER2 positive Stage IV breast cancer patient: 5 years term follow up case report by Matsumoto, Kizuki, Sakamoto, Masaaki, Machida, Youichi, Kurosumi, Masafumi, Fukuma, Eisuke

“…•Cryoablation is an alternative to mastectomy that can preserve the quality of life cryoablation may offer HER2+Stage IV BC patients a surgery free…”
Get full text

Optimal Treatment Duration of Neoadjuvant Endocrine Therapy for Women Aged 60 Years or Older with Estrogen Receptor-Positive, HER2-Negative Invasive Breast Cancer by Hayashi, Yuji, Takei, Hiroyuki, Saito, Tsuyoshi, Kai, Toshihiro, Inoue, Kenichi, Kurosumi, Masafumi, Ninomiya, Jun, on behalf of Saitama Breast Cancer Clinical Study Group (SBCCSG)

“…Background: Neoadjuvant endocrine therapy is not the standard of care for breast cancer, primarily because the optimal treatment duration remains unclear. This…”
Get full text

Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer by Kurozumi, Sasagu, Fujii, Takaaki, Matsumoto, Hiroshi, Inoue, Kenichi, Kurosumi, Masafumi, Horiguchi, Jun, Kuwano, Hiroyuki

“…The immune system affects all phases of tumor growth from initiation to progression and dissemination. Tumor-infiltrating lymphocytes (TILs) are mononuclear…”
Get full text

Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators by Inoue, Kenichi, Ninomiya, Jun, Saito, Tsuyoshi, Kimizuka, Kei, Kurosumi, Masafumi

“…To examine the efficacy and safety of induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin (ISMT) in Japanese…”
Get full text

Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy by Kurozumi, Sasagu, Yamaguchi, Yuri, Matsumoto, Hiroshi, Kurosumi, Masafumi, Hayashi, Shin-Ichi, Fujii, Takaaki, Horiguchi, Jun, Shirabe, Ken, Inoue, Kenichi

“…In this study, we investigated the relationships of pathological response after neoadjuvant chemo-endocrine therapy with alterations in the Ki67 labeling index…”
Get full text

Nuclear grade and comedo necrosis of ductal carcinoma in situ as histopathological eligible criteria for the Japan Clinical Oncology Group 1505 trial: an interobserver agreement study by Tsuda, Hitoshi, Yoshida, Masayuki, Akiyama, Futoshi, Ohi, Yasuyo, Kinowaki, Keiichi, Kumaki, Nobue, Kondo, Yuzuru, Saito, Akihisa, Sasaki, Eiichi, Nishimura, Rieko, Fujii, Satoshi, Homma, Keiichi, Horii, Rie, Murata, Yuya, Itami, Makiko, Kajita, Sabine, Kato, Hiroyuki, Kurosumi, Masafumi, Sakatani, Takashi, Shimizu, Shigeki, Taniguchi, Kohei, Tamiya, Sadafumi, Nakamura, Harumi, Kanbayashi, Chizuko, Shien, Tadahiko, Iwata, Hiroji

“…Abstract Objective The Japan Clinical Oncology Group 1505 trial is a single-arm multicentre prospective study that examined the possibility of non-surgical…”
Get full text

Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafur–uracil with CMF (N·SAS-BC 01 trial and CUBC trial) by Ohno, Shinji, Saji, Shigehira, Masuda, Norikazu, Tsuda, Hitoshi, Akiyama, Futoshi, Kurosumi, Masafumi, Shimomura, Akihiko, Sato, Nobuaki, Takao, Shintaro, Ohsumi, Shozo, Tokuda, Yutaka, Inaji, Hideo, Watanabe, Toru, Ohashi, Yasuo

“…Purpose To evaluate the efficacies of cyclophosphamide, methotrexate, and fluorouracil (CMF) and tegafur–uracil (UFT) as adjuvant therapy in patients with…”
Get full text

Radiotherapy for localized gastric mucosa–associated lymphoid tissue lymphoma: long-term outcomes over 10 years by Ohkubo, Yu, Saito, Yoshihiro, Ushijima, Hiroki, Onishi, Masahiro, Kazumoto, Tomoko, Saitoh, Jun-ichi, Kubota, Nobuko, Kobayashi, Hirofumi, Maseki, Nobuo, Nishimura, Yu, Kurosumi, Masafumi

“…Abstract This study aimed to assess the long-term outcomes of radiotherapy in patients with localized gastric mucosa–associated lymphoid tissue (MALT)…”
Get full text

Recent trends of HER-2 testing and trastuzumab therapy for breast cancer by Kurosumi, Masafumi

“…Molecular-targeted therapy using trastuzumab, a humanized monoclonal antibody against human epidermal growth factor receptor type-2 (HER-2), is considered to…”
Get full text

The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways by Yanagisawa, Junn, Kajiro, Masashi, Hirota, Ryuichi, Nakajima, Yuka, Kawanowa, Kaori, So-ma, Kae, Ito, Ichiaki, Yamaguchi, Yuri, Ohie, Sho-hei, Kobayashi, Yasuhito, Seino, Yuko, Kawano, Miwako, Kawabe, Yoh-ichi, Takei, Hiroyuki, Hayashi, Shin-ichi, Kurosumi, Masafumi, Murayama, Akiko, Kimura, Keiji

“…CHIP is a U-box-type ubiquitin ligase that induces ubiquitylation and degradation of its substrates, which include several oncogenic proteins. The relationship…”
Get full text

Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer by Kurozumi, Sasagu, Yamaguchi, Yuri, Matsumoto, Hiroshi, Inoue, Kenichi, Kurosumi, Masafumi, Oyama, Tetsunari, Horiguchi, Jun, Fujii, Takaaki, Shirabe, Ken

“…The human epidermal growth factor receptor (HER) family plays a vital role in the development of resistance to treatments in estrogen receptor (ER)-positive…”
Get full text

Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG by Kuroi, Katsumasa, Toi, Masakazu, Ohno, Shinji, Nakamura, Seigo, Iwata, Hiroji, Masuda, Norikazu, Sato, Nobuaki, Tsuda, Hitoshi, Kurosumi, Masafumi, Akiyama, Futoshi

“…Background Neoadjuvant chemotherapy (NAC) has been accepted as one of the standard treatments for operable breast cancer. However, the term pathologic complete…”
Get full text

Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG by Kuroi, Katsumasa, Toi, Masakazu, Ohno, Shinji, Nakamura, Seigo, Iwata, Hiroji, Masuda, Norikazu, Sato, Nobuaki, Tsuda, Hitoshi, Kurosumi, Masafumi, Akiyama, Futoshi

“…Purpose In the past decade, JBCRG has conducted three studies of neoadjuvant chemotherapy which have examined sequential combination of fluorouracil,…”
Get full text